美欧卡霉素治疗61例呼吸道感染的临床评价  

CLINICAL EVALUATION OF MIOCAMYCIN IN THE TREATMENT OF RESPIRATORY TRACT INFECTIONS

作　　者：侯芳[1] 李家泰[1] 尹非[1] 崔德健[2] 

机构地区：[1]北京医科大学临床药理研究所,北京100034 [2]解放军304医院

出　　处：《中国新药杂志》1993年第3期42-44,共3页Chinese Journal of New Drugs

摘　　要：用美欧卡霉素(200mg tid 或400mg bid～tid,疗程7～14d)治疗轻、中度呼吸道感染61例,结果显示临床痊愈显效率为91.8%,治疗前细菌阳性率为86.9%,治疗后53例细菌阳性中47例细菌消除,细菌阴转率为88.7%,共分离致病菌56株,治疗后51株消除,细菌清除率为91.1%,不良反应发生率为6.56%。结果表明,美欧卡霉素对临床上 G~+菌、流感杆菌所致轻、中度呼吸道感染抗菌作用较好,安全有效。61 patients with respiratory tract infections were treated with mio-camycin(daily dosage 600～1200mg,divided two to three times,orally for 7～14days).The results showed that the clinical efficacy rate of miocamycin was 91.8%.The bacteriological responses occured in 47 of 53 organisms,so the bacteriological effi-cacy rate was 88.7%.51 of total 56 strains from patients were eradicated(91.1%).Adverse reactions observed in 4(6.56%)of 61 cases due to miocamycin were rare andnot severe.

关 键 词：美欧卡霉素 呼吸道感染 抗菌素 

分 类 号：R974[医药卫生—药品]